about
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter.Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change.The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyEfavirenz concentrations in CSF exceed IC50 for wild-type HIV.Neurocognitive functioning in acute or early HIV infection.Brain morphometric correlates of metabolic variables in HIV: the CHARTER study.Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected peoplePredictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.Neurocognitive impact of substance use in HIV infection.Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder.Therapeutic amprenavir concentrations in cerebrospinal fluidAbdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation.Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensityMitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort.Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationMitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patientsEtravirine in CSF is highly protein boundHuman immunodeficiency virus protease inhibitors and risk for peripheral neuropathyLow atazanavir concentrations in cerebrospinal fluidIncreases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionCSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease.Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemCD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyHIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex.Reply to Haddow et al.The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.Higher Anti-CMV IgG Concentrations are Associated with Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy.White matter damage, neuroinflammation, and neuronal integrity in HAND
P50
Q33692525-F2D26458-13C2-4621-978F-F032B2A4A5F4Q33842454-375F4609-B7E3-4069-9459-C8AB4EB0149AQ33849136-47F50B09-8965-4496-A79F-EB50DBD9905AQ33938797-9BED7934-8A0D-40F9-828D-D64FC02CD5F1Q33987146-B6159825-81F6-4F47-8176-27D16CC6FA13Q34309626-61742915-CA76-40FC-91E0-18AFA1E1DB19Q34370880-B9632AAD-35AC-41B2-A92B-D9D310AB2DD4Q34481352-20D7D646-B11C-4E76-BB84-313A769CE67FQ34544921-D024ED7F-6C35-4E7F-A36F-74D8EA2B427FQ34716740-B50B6A0C-32CF-4F50-B584-8AACA929ED25Q35003408-912675CA-E4BC-4BC3-ADB7-5D244EEDF92AQ35106267-37449B7D-8F1B-422C-B3F4-3A643A46BB2CQ35217892-76603A41-7FC5-4B0B-9493-0D2A6915EEFAQ35245735-344240EF-2FF6-4B3C-B4B9-755C53B97DAFQ35639872-C1D0C645-97B0-4897-BE0B-C944EAC3C86EQ35758653-FD674A5F-06F3-4325-9CBA-85C3F38F14ECQ35867483-97F475B1-0980-427F-920D-D1E717FC6244Q36001196-08E0836A-B89B-4211-8035-0556BA2C02D9Q36075099-D527F3BC-8A7A-4200-AA6A-2A4B5FDFD234Q36141245-9D806751-F4BB-4E30-A853-DCF8E61D5578Q36266689-7F82389D-20D1-44D1-923A-FADC61882D02Q36487415-0F353ADD-E656-4317-B78B-F6CA89DF66E8Q36593671-5CFE8CD9-8812-406E-966A-E792A9C37AB0Q36653563-D849F7A4-DE55-4AFF-B1FB-F7A18A8C4701Q36664960-0289F11C-253A-4544-86B3-C506317D8F09Q36762988-A7F87EC9-1AA6-4C81-AE6B-BD3F97F5A074Q37019423-569E5AA6-D338-4FE3-BAD9-821970CE64AEQ37097831-F341D082-1AE0-49F7-A737-ED745A2D8F03Q37181324-442C19A6-A841-481D-A92A-2396C9F48EE9Q37226549-7D28614C-568D-4998-AB60-C7CA194724EAQ37390163-3FEB043A-289C-4B28-B378-C21C1077703CQ37402458-C01A0C03-3CB2-470A-A528-2541718FE215Q37416972-C19F4E23-6447-4AD1-B097-934A9E2157E2Q40478740-BAF5396C-1AF6-44AB-AB0A-EE6970954F3EQ40846562-3BA6E103-EBCB-442B-94E1-333C365E56A6Q42047014-97BD0F67-9CEA-4BBB-8E1B-D984DDE8630EQ42580831-00A68A5A-23D5-4192-9B00-8033BFEEFB11Q46880722-46F5C69C-D701-452E-9004-833327550478Q54262086-4FA42082-AB14-4E0D-B174-28E512AAE329Q57022314-0ED1118F-0D11-46BC-B10E-A55E1D89577F
P50
name
CHARTER Group
@en
type
label
CHARTER Group
@en
prefLabel
CHARTER Group
@en